chronic sulfonylurea drug therapy of patients with non-insulin-dependent diabetes mellitus enhances pancreatic islet sensitivity to glucose , leading to increased insulin secretion , suppression of hepatic glucose production , and a decline in the steady-state fasting glucose level .
C0011849
non-insulin-dependent diabetes mellitus
C0022131
pancreatic islet